MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 81 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,381,032 | -21.2% | 2,904,476 | +6.3% | 0.05% | -17.2% |
| Q2 2023 | $29,661,375 | +111.3% | 2,731,250 | +34.2% | 0.06% | +106.5% |
| Q1 2023 | $14,038,050 | +71.8% | 2,034,500 | -0.9% | 0.03% | +55.0% |
| Q4 2022 | $8,168,950 | -0.7% | 2,052,500 | +65.9% | 0.02% | 0.0% |
| Q3 2022 | $8,229,000 | +34.7% | 1,237,500 | -2.0% | 0.02% | +42.9% |
| Q2 2022 | $6,111,000 | -48.2% | 1,262,500 | 0.0% | 0.01% | -36.4% |
| Q1 2022 | $11,804,000 | -21.3% | 1,262,500 | 0.0% | 0.02% | -18.5% |
| Q4 2021 | $14,999,000 | +4.4% | 1,262,500 | 0.0% | 0.03% | -3.6% |
| Q3 2021 | $14,367,000 | -36.6% | 1,262,500 | 0.0% | 0.03% | -36.4% |
| Q2 2021 | $22,649,000 | +0.0% | 1,262,500 | -13.7% | 0.04% | -4.3% |
| Q1 2021 | $22,640,000 | +26.9% | 1,462,500 | 0.0% | 0.05% | +17.9% |
| Q4 2020 | $17,843,000 | -5.1% | 1,462,500 | 0.0% | 0.04% | -17.0% |
| Q3 2020 | $18,793,000 | – | 1,462,500 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |